

DOCKET NO.: CEPH-2313 (CP188-C)  
 Application No.: 10/685,923  
 Office Action Dated: April 13, 2005


PATENT  
 REPLY FILED UNDER EXPEDITED  
 PROCEDURE PURSUANT TO  
 37 CFR § 1.116

This listing of claims will replace all prior versions, and listings, of claims in the application.

*Listing of Claims*

Claims 1 to 44 (*cancelled*)

45. (*new*) A compound having the Formula I:



wherein:

Q is (lower alkyl)-S(O)<sub>2</sub>- or arylalkyl-OC(=O)-, said arylalkyl having from 7 to 15 carbons;

Aaa is an amino acid;

n is 0 or 1;

M is a carbon atom;

R<sup>1</sup> is selected from the group consisting of alkyl having from one to 6 carbons and alkoxyalkyl, said alkyl and alkoxyalkyl groups being optionally substituted with phenyl;

R<sup>2</sup> is benzyl;

R<sup>3</sup> is H;

q is 1;

Z is -C(=O)C(=O)NH-X-A<sup>1</sup>-K;

X is a bond;

A<sup>1</sup> is -CH<sub>2</sub>-CH<sub>2</sub>-, -CH<sub>2</sub>-CH(CH<sub>3</sub>)-, or -CH(CH<sub>3</sub>)-CH<sub>2</sub>-;

K is -NHSO<sub>2</sub>R<sup>8</sup> or -SO<sub>2</sub>NH(R<sup>8</sup>);

R<sup>8</sup> is aryl, said aryl being substituted with one J group;

J is piperazinyl-CH<sub>2</sub>- optionally substituted by a J<sup>1</sup> group;

DOCKET NO.: CEPH-2313 (CP188-C)  
 Application No.: 10/685,923  
 Office Action Dated: April 13, 2005

PATENT  
 REPLY FILED UNDER EXPEDITED  
 PROCEDURE PURSUANT TO  
 37 CFR § 1.116

$J^1$  is selected from the group consisting of halogen, CN, nitro, lower alkyl, cycloalkyl, heterocycloalkyl, heteroalkyl, halogenated alkyl, aryloxyalkyl, alkylthio, alkylsulfonyl, aryl, heteroaryl, arylalkyl, arylalkyloxy, arylsulfonyl, heteroarylsulfonyl, alkoxycarbonyl, alkoxyalkyl, acyl, alkoxy, hydroxy, carboxy, hydroxyalkyl, amino, alkylamino, and aminoalkyl, said amino group or said amino group of said aminoalkyl or alkylamino group being optionally substituted with an acyl group, an alkoxy group, or with 1 to 3 aryl, lower alkyl, cycloalkyl, or alkoxyalkyl groups; and said aryl, heteroaryl, heterocycloalkyl, and heteroalkyl groups being further optionally substituted by a  $J^2$  group; and

$J^2$  is selected from a group consisting of halogen, CN, nitro, lower alkyl, halogenated alkyl, alkylthio, alkylsulfonyl, alkoxycarbonyl, alkoxyalkyl, acyl, alkoxy, hydroxy, carboxy, hydroxyalkyl, amino, alkylamino, and aminoalkyl;

or a pharmaceutically acceptable salt thereof.


46. (new) The compound of claim 45, wherein Q is (lower alkyl)-S(O)<sub>2</sub>-.

47. (new) The compound of claim 45, wherein  $R^1$  is -CH<sub>2</sub>OCH<sub>2</sub>(C<sub>6</sub>H<sub>5</sub>).

48. (new) The compound of claim 45, wherein Q is methyl-S(O)<sub>2</sub>- and  $R^8$  is substituted phenyl.

49. (new) The compound of claim 45, wherein  $R^1$  is -CH<sub>2</sub>OCH<sub>2</sub>(C<sub>6</sub>H<sub>5</sub>), Q is methyl-S(O)<sub>2</sub>-, and  $R^8$  is substituted phenyl.

50. (new) A compound having the formula:



wherein

DOCKET NO.: CEPH-2313 (CP188-C)  
 Application No.: 10/685,923  
 Office Action Dated: April 13, 2005

PATENT  
 REPLY FILED UNDER EXPEDITED  
 PROCEDURE PURSUANT TO  
 37 CFR § 1.116

W is selected from the group consisting of: Ms-D-Ser(Bn), Ms-L-Ser(Bn),  
 Ms-D-Thr(Bn), Ms-D-Phe, and Cbz-Leu-Leu;

R is selected from the group consisting of:

-CH<sub>2</sub>CH<sub>2</sub>NHSO<sub>2</sub>-C<sub>6</sub>H<sub>4</sub>-CH<sub>2</sub>-(4-(CH<sub>3</sub>COPh)piperazin-1-yl);  
 -CH<sub>2</sub>CH<sub>2</sub>NHSO<sub>2</sub>-C<sub>6</sub>H<sub>4</sub>-CH<sub>2</sub>-(4-(PhCH<sub>2</sub>)piperazin-1-yl);  
 -CH<sub>2</sub>CH<sub>2</sub>NHSO<sub>2</sub>-C<sub>6</sub>H<sub>4</sub>-CH<sub>2</sub>-(4-(CH<sub>3</sub>CO)piperazin-1-yl);  
 -CH<sub>2</sub>CH<sub>2</sub>NHSO<sub>2</sub>-C<sub>6</sub>H<sub>4</sub>-CH<sub>2</sub>-((4-pyrid-2-yl) piperazine-1-yl);  
 -CH<sub>2</sub>CH<sub>2</sub>NHSO<sub>2</sub>-C<sub>6</sub>H<sub>4</sub>-CH<sub>2</sub>-(4-ethylpiperazin-1-yl);  
 -CH<sub>2</sub>CH<sub>2</sub>NHSO<sub>2</sub>-C<sub>6</sub>H<sub>4</sub>-CH<sub>2</sub>-(4-(CH<sub>3</sub>SO<sub>2</sub>)piperazin-1-yl); and  
 -CH<sub>2</sub>CH<sub>2</sub>NHSO<sub>2</sub>-C<sub>6</sub>H<sub>4</sub>-CH<sub>2</sub>-((4-pyrimid-2-yl)piperazine-1-yl),

or a pharmaceutically acceptable salt thereof.

51. (new) The compound of claim 50, wherein W and R are selected in accordance with the following table:

	W	R
1	Ms-D-Ser (Bn)	-CH <sub>2</sub> CH <sub>2</sub> NHSO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub> -CH <sub>2</sub> -(4-(CH <sub>3</sub> COPh)piperazin-1-yl);
2	Ms-D-Ser (Bn)	-CH <sub>2</sub> CH <sub>2</sub> NHSO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub> -CH <sub>2</sub> -(4-(PhCH <sub>2</sub> )piperazin-1-yl);
3	Ms-D-Ser (Bn)	-CH <sub>2</sub> CH <sub>2</sub> NHSO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub> -CH <sub>2</sub> -(4-(CH <sub>3</sub> CO)piperazin-1-yl);
4	Ms-D-Ser (Bn)	-CH <sub>2</sub> CH <sub>2</sub> NHSO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub> -CH <sub>2</sub> -((4-pyrid-2-yl) piperazine-1-yl);
5	Ms-D-Ser (Bn)	-CH <sub>2</sub> CH <sub>2</sub> NHSO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub> -CH <sub>2</sub> -(4-ethylpiperazin-1-yl);
6	Ms-D-Ser (Bn)	-CH <sub>2</sub> CH <sub>2</sub> NHSO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub> -CH <sub>2</sub> -(4-(CH <sub>3</sub> SO <sub>2</sub> )piperazin-1-yl);
7	Ms-D-Ser (Bn)	-CH <sub>2</sub> CH <sub>2</sub> NHSO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub> -CH <sub>2</sub> -((4-pyrimid-2-yl)piperazine-1-yl),

or a pharmaceutically accepted salt thereof.

52. (new) A pharmaceutical composition for inhibiting a serine protease or a cysteine protease, comprising:

a compound of claim 45; and  
 a pharmaceutically acceptable carrier.

**DOCKET NO.:** CEPH-2313 (CP188-C)  
**Application No.:** 10/685,923  
**Office Action Dated:** April 13, 2005

**PATENT  
REPLY FILED UNDER EXPEDITED  
PROCEDURE PURSUANT TO  
37 CFR § 1.116**

53. *(new)* A pharmaceutical composition for inhibiting a serine protease or a cysteine protease: comprising:  
a compound of claim 50; and  
a pharmaceutically acceptable carrier.
54. *(new)* A pharmaceutical composition for inhibiting a serine protease or a cysteine protease, comprising:  
a compound of claim 51; and  
a pharmaceutically acceptable carrier.